A Phase 2 interventional study of PG4 and 20-valent pneumococcal conjugate vaccine (20vPnC) in Pneumococcal Disease, sponsored by Pfizer. Active, not recruiting at 67 sites in 2 countries. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Pneumococcal Infections by Pfizer — 4 open to participants now, 8 under way, 5 of them phase 3. Pneumococcal Infections · Pfizer.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 28th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 66th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →4 of the 75 studies in Pneumococcal Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Pfizer · Sites in United States, Finland, Poland and 1 more country
Ages 15 mo–17 yrs · Healthy volunteers
Pfizer · Sites in United States, Japan, Puerto Rico
Ages 42 days–211 days · Healthy volunteers
Pfizer · Sites in United States, Argentina, Australia and 8 more countries
Ages 42 days–98 days · Healthy volunteers
By country, each count listing its studies:
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 42 Days to 98 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 9 · Phase 3 33 · Phase 4 7
First in 2001; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 605 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 570 across the 57 interventional studies, 1,050 across the 18 observational. Of the 67 that completed or were terminated, 45 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Pneumococcal Infections by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07794748Phase 3PfizerA Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults | 2027-04-26 |
| NCT06622109PfizerA Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months | 2026-12-04 |
| NCT06524414PfizerA Study to Learn About How a New Pneumococcal Vaccine Works in Infants | 2027-03-04 |
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Pneumococcal Infections by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in use, 20vPnC (Prevnar 20®) or another licensed pneumococcal vaccine.
To ensure that the new vaccine (PG4) stays stable, it is placed in a liquid mixture of sterile water and other substances (a solution). This study will also test if there is a difference in the safety and immune effects of the new pneumococcal vaccine when it is one type of solution compared to when it is in a different type of solution.
The immune response is how the body's cells; tissues and organs work together to protect the body from infection. Blood samples will be used to measure the amount of antibodies produced after the vaccination. Antibodies are proteins that protect you when an unwanted germ enters the body. This will help understand how well the new pneumococcal vaccine works. This vaccine can possibly provide protection against pneumococcal disease. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae.
This study is seeking participants who are:
There are four groups in this study. All participants will be assigned to one of the four groups. All study vaccines will be given as a single shot into the left thigh muscle. Participants in the three groups will have 3 blood samples collected during the 1 and a half years they are in the study.
The first 400 participants who enter the study will be assigned to either Group 1 or Group 2. Half the participants in Group 1 and half the participants in Group 2 will receive 4 doses at 2, 4, 6, and 12 to 15 months of age of PG4 mixed in the first solution. The other half of the participants in Groups 1 and 2 will receive 4 doses of 20vPnC (Prevnar 20®) at 2, 4, 6, and 12 to 15 months of age. The main difference between Groups 1 and 2 is that participants in Group 2 will have the first blood sample collected at an earlier time than those in Group 1.
Once 400 participants have been assigned to Groups 1 and 2 then 100 new participants will be assigned to Group 3. Half the participants in Group 3 will receive PG4 in the second solution at 2, 4, 6, and 12 to 15 months of age. The other half of the participants in Groups 3 will receive 4 doses of 20vPnC (Prevnar 20®) at 2, 4, 6, and 12 to 15 months of age.
Once the 100 participants have been assigned to Group 3 then 100 new participants will be assigned to Group 4. Half the participants in Group 4 will receive PG4 in the first solution at 2, 4, 6, and 12 to 15 months of age. The other half of the participants in Group 4 will receive 4 doses of a licensed pneumococcal comparator vaccine at 2, 4, 6, and 12 to 15 months of age.
Participants will take part in this study for about 16 to 19 months (about 1 and a half years). During this time, participants will have 6 study clinic visits and 1 to 2 phone calls. At these study clinic visits, parent(s) or legal guardian(s) will be asked if the participant experienced any side effects. A side effect is an unintentional or unexpected reaction to a vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multivalent Pneumococcal Vaccine
Biological: PG4
20-valent pneumococcal conjugate vaccine (20vPnC)
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)
Multivalent Pneumococcal Vaccine
Biological: PG4
20-valent pneumococcal conjugate vaccine (20vPnC)
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)
Multivalent Pneumococcal Vaccine
Biological: PG4
20-valent pneumococcal conjugate vaccine (20vPnC)
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)
Multivalent Pneumococcal Vaccine
Biological: PG4
15-valent pneumococcal conjugate vaccine (PCV15)
Biological: 15-valent pneumococcal conjugate vaccine (PCV15)
Multivalent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine
Also known as: Prevnar 20
15-valent pneumococcal conjugate vaccine
Also known as: PCV15
Percentage of participants reporting local reactions within 7 days after each dose
Prompted local reactions after each dose
Time frame: Day 7
Percentage of participants reporting systemic events within 7 days after each dose
Prompted systemic reactions after each dose
Time frame: Day 7
Percentage of participants reporting adverse events (AEs)
AEs occurring from Dose 1 to 1 month after Dose 2
Time frame: Dose 1 to 1 month after Dose 3
Percentage of participants reporting AEs
AEs occurring from Dose 4 to 1 month after Dose 4
Time frame: Dose 4 to 1 month after Dose 4
Percentage of participants reporting serious adverse events (SAEs)
SAEs occurring from Dose 1 to 6 months after Dose 4
Time frame: Dose 1 to 6 months after Dose 4
Pneumococcal immunoglobulin G (IgG) geometric mean concentrations (GMCs)
Pneumococcal IgG GMCs 1 month after Dose 4
Time frame: 1 month after Dose 4
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Jul 2024 (actual). Primary completion is estimated for Mar 2027, 31 months after the start.
Of 23 phase 2 interventional studies under Pneumococcal Infections, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 31 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion May 2027 → Mar 2027 and completion May 2027 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.